{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu Y"],"funding":["Major Basic Research Project of Shandong Provincial Natural Science Foundation","Taishan Scholar's program","National Natural Science Foundation of China","Special Project of Central Government for Local Science and Technology Development of Shandong Province","Natural Science Foundation of Shandong Province for Excellent Youth Scholars","Science and Technology development plan project of Medicine and health care of Shandong province","Development plan of Youth Innovation Team in Colleges and universities of Shandong Province","Yantai Development Project of University and Government Integration","Yantai Science and Technology Innovation Development Plan Project","Natural Science Foundation of Shandong Province","Scientific research foundation of Binzhou Medical College","Shandong Province Higher Educational Youth Innovation Science and Technology Program","Key R&D Program of Shandong Province"],"pagination":["e2307271"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10853751"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(6)"],"pubmed_abstract":["Chemotherapy is widely used to treat colorectal cancer (CRC). Despite its substantial benefits, the development of drug resistance and adverse effects remain challenging. This study aimed to elucidate a novel role of glucagon in anti-cancer therapy. In a series of in vitro experiments, glucagon inhibited cell migration and tube formation in both endothelial and tumor cells. In vivo studies demonstrated decreased tumor blood vessels and fewer pseudo-vessels in mice treated with glucagon. The combination of glucagon and chemotherapy exhibited enhanced tumor inhibition. Mechanistic studies demonstrated that glucagon increased the permeability of blood vessels, leading to a pronounced disruption of vessel morphology. Signaling pathway analysis identified a VEGF/VEGFR-dependent mechanism whereby glucagon attenuated angiogenesis through its receptor. Clinical data analysis revealed a positive correlation between elevated glucagon expression and chemotherapy response. This is the first study to reveal a role for glucagon in inhibiting angiogenesis and vascular mimicry. Additionally, the delivery of glucagon-encapsulated PEGylated liposomes to tumor-bearing mice amplified the inhibition of angiogenesis and vascular mimicry, consequently reinforcing chemotherapy efficacy. Collectively, the findings demonstrate the role of glucagon in inhibiting tumor vessel network and suggest the potential utility of glucagon as a promising predictive marker for patients with CRC receiving chemotherapy."],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Glucagon Enhances Chemotherapy Efficacy By Inhibition of Tumor Vessels in Colorectal Cancer."],"pmcid":["PMC10853751"],"funding_grant_id":["tsqn201812100","tsqn202103112","BY2018KYQD08 YY","2023CXPT012TG","2019WS319 YM","BY2017KYQD09 XYX","31800985 XYX","ZR2016JL026 TG","ZR2020QH242YY","2019KJE013 TG","ZR2021MH292ZY","2023JCYJ072 XYX","2019XDRHXMPT14 TG","2017WS694 XYX","2021KJ052 WPF","BY2019KYQD01ZY","YDZX20203700001291 TG","tstp20221145","31771284 TG","BY2021KYQD21","ZR2019ZD27 TG"],"pubmed_authors":["Zhang G","Peng Y","Mi J","Zhao Y","Wei P","Qi X","Jiang W","Sun D","Chen X","Zhang C","Wu X","Yan M","Ni F","Tian G","Zhou Y","Yang C","Li M","An B","Yang Y","Li S","Zhang Y","He X","Yao C","Xu Y","Zhu S"],"additional_accession":[]},"is_claimable":false,"name":"Glucagon Enhances Chemotherapy Efficacy By Inhibition of Tumor Vessels in Colorectal Cancer.","description":"Chemotherapy is widely used to treat colorectal cancer (CRC). Despite its substantial benefits, the development of drug resistance and adverse effects remain challenging. This study aimed to elucidate a novel role of glucagon in anti-cancer therapy. In a series of in vitro experiments, glucagon inhibited cell migration and tube formation in both endothelial and tumor cells. In vivo studies demonstrated decreased tumor blood vessels and fewer pseudo-vessels in mice treated with glucagon. The combination of glucagon and chemotherapy exhibited enhanced tumor inhibition. Mechanistic studies demonstrated that glucagon increased the permeability of blood vessels, leading to a pronounced disruption of vessel morphology. Signaling pathway analysis identified a VEGF/VEGFR-dependent mechanism whereby glucagon attenuated angiogenesis through its receptor. Clinical data analysis revealed a positive correlation between elevated glucagon expression and chemotherapy response. This is the first study to reveal a role for glucagon in inhibiting angiogenesis and vascular mimicry. Additionally, the delivery of glucagon-encapsulated PEGylated liposomes to tumor-bearing mice amplified the inhibition of angiogenesis and vascular mimicry, consequently reinforcing chemotherapy efficacy. Collectively, the findings demonstrate the role of glucagon in inhibiting tumor vessel network and suggest the potential utility of glucagon as a promising predictive marker for patients with CRC receiving chemotherapy.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-06-03T20:06:43.041Z","creation":"2025-04-05T14:51:25.994Z"},"accession":"S-EPMC10853751","cross_references":{"pubmed":["38072640"],"doi":["10.1002/advs.202307271"]}}